Efficacy of Copanlisib Monotherapy in Patients With Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis From the CHRONOS-1 Trial

被引：0
|
作者：
Martin, Peter [1 ]
机构：
[1] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, Med, New York, NY 10065 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [41] Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma
    Vanazzi, Anna
    Grana, Chiara
    Crosta, Cristiano
    Pruneri, Giancarlo
    Rizzo, Stefania
    Radice, Davide
    Pinto, Antonello
    Calabrese, Liliana
    Paganelli, Giovanni
    Martinelli, Giovanni
    HEMATOLOGICAL ONCOLOGY, 2014, 32 (01) : 10 - 15
  • [42] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
    Phillips, Tycel J.
    Corradini, Paolo
    Gurion, Ronit
    Patti, Caterina
    Tani, Monica
    Avigdor, Abraham
    Jurczak, Wojciech
    Mehta, Amitkumar
    Zinzani, Pier Luigi
    Lossos, Izidore S.
    Thieblemont, Catherine
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2020, 136
  • [43] HIGH-DOSE CLARITHROMYCIN IS A FEASIBLE AND ACTIVE MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL MARGINAL ZONE LYMPHOMA: FINAL RESULTS OF A SINGLE-ARM PHASE II TRIAL
    Ferreri, A. J. M.
    Sassone, S.
    Kiesewetter, B.
    Scarfo, L.
    Citterio, G.
    Foppoli, M.
    Calimeri, T.
    Raderer, M.
    HAEMATOLOGICA, 2015, 100 : 93 - 94
  • [44] Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): Final analysis of MAGNOLIA (BGB-3111-214)
    Linton, Kim M.
    Trotman, Judith
    Mckay, Pamela
    Ardeshna, Kirit
    Iyengar, Sunil
    Tedeschi, Alessandra
    Hu, Bei
    Leitch, Sophie
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Browett, Peter
    Ke, Xiaoyan
    Portell, Craig A.
    Thieblemont, Catherine
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Opat, Stephen
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 12 - 12
  • [45] Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial
    Jacobsen, Eric
    Ura, Juraj
    Ardeshna, Kirit
    Cherry, Mohamad
    Offner, Fritz
    Mayer, Jiri
    Bijou, Fontanet
    Tani, Monica
    Musuraca, Gerardo
    Merli, Michele
    Marasca, Roberto
    Weaver, David T.
    Lustgarten, Stephanie
    Youssoufian, Hagop
    Zinzani, Pier Luigi
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S20 - S20
  • [46] Characterization of Duvelisib in Patients with Refractory Marginal Zone Lymphoma: Data from the Phase 2 DYNAMO Trial
    Jacobsen, Eric
    Duras, Juraj
    Ardeshna, Kirit
    Cherry, Mohamad
    Offner, Fritz
    Mayer, Jiri
    Bijou, Fontanet
    Tani, Monica
    Musuraca, Gerardo
    Merli, Michele
    Marasca, Roberto
    Weaver, David
    Lustgarten, Stephanie
    Youssoufian, Hagop
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S312 - S313
  • [47] Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
    Opat, Stephen
    Tedeschi, Alessandra
    Hu, Bei
    Linton, Kim M.
    McKay, Pamela
    Chan, Henry
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Browett, Peter J.
    Ke, Xiaoyan
    Portell, Craig A.
    Thieblemont, Catherine
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Trotman, Judith
    BLOOD, 2022, 140
  • [48] SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)
    Ferreri, A. J.
    Cecchetti, C.
    Kiesewetter, B.
    Sassone, M.
    Calimeri, T.
    Scarfo, L.
    Raderer, M.
    HAEMATOLOGICA, 2016, 101 : 104 - 105
  • [49] Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
    Scarfo, Lydia
    Ferrari, Silvia
    Frustaci, Anna Maria
    Tani, Monica
    Bari, Alessia
    Scarano, Eloise
    Colia, Maria
    Ranghetti, Pamela
    Angelillo, Piera
    Ronchi, Paola
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Ghia, Paolo
    BLOOD ADVANCES, 2022, 6 (18) : 5356 - 5359
  • [50] The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
    Opat, Stephen
    Tedeschi, Alessandra
    Linton, Kim
    McKay, Pamela
    Hu, Bei
    Chan, Henry
    Jin, Jie
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Coleman, Morton
    Thieblemont, Catherine
    Browett, Peter
    Ke, Xiaoyan
    Sun, Mingyuan
    Marcus, Robert
    Portell, Craig A.
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Mapp, Sally
    Ho, Shir-Jing
    Talaulikar, Dipti
    Zhou, Ke-Shu
    Co, Melannie
    Li, Xiaotong
    Zhou, Wenxiao
    Cappellini, Massimo
    Tankersley, Chris
    Huang, Jane
    Trotman, Judith
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6323 - 6332
12345